Literature DB >> 1347031

The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa.

S Hsing1, Z Gatmaitan, I M Arias.   

Abstract

Gp170 is a transmembrane glycoprotein that is overexpressed in multidrug-resistant tumor cells and is present in the apical plasma membrane domain of small intestinal mucosal cells. The function of Gp170 was studied in the small intestine of the rat. Jejunal and ileal brush border membrane vesicles, but not basolateral membrane vesicles, manifested adenosine triphosphate (ATP)-dependent transport of daunomycin, a substrate for Gp170, and contained a approximately 170-kilodalton protein that reacts with anti-Gp170 monoclonal antibody. Whereas ATP supported daunomycin transport, nonhydrolyzable ATP analogues were ineffective. ATP-dependent daunomycin transport by brush border vesicles was unidirectional (inside to outside) and temperature dependent and was blocked by Gp170 inhibitors but not by taurocholate or bromsulphalein glutathione. Studies using everted small intestine revealed transport of rhodamine 123, a Gp170 substrate, from the serosal surface through the mucosa and inhibition by Gp170 inhibitors. These results suggest that Gp170 in rat small intestinal brush border membrane vesicles is an ATP-dependent efflux pump responsible for the transport of Gp170 substrates into the small intestinal lumen. Gp170 may protect against exogenously derived potentially damaging hydrophobic cations and contribute to the rarity of small intestinal cancer in humans and many animals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347031     DOI: 10.1016/0016-5085(92)90173-v

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  28 in total

1.  Transepithelial transport of diphenhydramine across monolayers of the human intestinal epithelial cell line Caco-2.

Authors:  H Mizuuchi; T Katsura; Y Hashimoto; K Inui
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

2.  Prodrug and analog approaches to improving the intestinal absorption of a cyclic peptide, GPIIb/IIIa receptor antagonist.

Authors:  H Saitoh; B J Aungst
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 3.  Carrier-mediated intestinal transport of drugs.

Authors:  A Tsuji; I Tamai
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 4.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist.

Authors:  B J Aungst; H Saitoh
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

6.  Organ clearance concepts: new perspectives on old principles.

Authors:  G L Sirianni; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

Review 7.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 8.  Drug exsorption from blood into the gastrointestinal tract.

Authors:  K Arimori; M Nakano
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

9.  Cloning and regulation of the rat mdr2 gene.

Authors:  P C Brown; S S Thorgeirsson; J A Silverman
Journal:  Nucleic Acids Res       Date:  1993-08-11       Impact factor: 16.971

10.  Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.

Authors:  V D Makhey; A Guo; D A Norris; P Hu; J Yan; P J Sinko
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.